[1] H. Moore and N. K, LI., "A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction," Theoretical Biology vol. 227, pp. 513-523, 2004.
[2] R. Padhi and M. Kothari, "An optimal dynamic inversion-based neuro-adaptive approach for treatment of chronic myelogenous leukemia," computer methods and programs in biomedicine, vol. 87, pp. 208-224, 2007.
[3] Paula, Chronic Myeloid Leukemia Booklet: The Leukemia & Lymphoma Society, revised in 2012.
[4] C. V. Cotta and C. E. Bueso-Ramos, "New insights into the pathobiology and treatment of chronic myelogenous leukemia," Annals of Diagnostic Pathology vol. 11, pp. 68, 2007.
[5] M. Baccarani and et.al., " Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia," The American Society of Hematology, vol. Blood 104 (13), pp. 4245-4251, 2004.
[6] T. Thiesing and et.al., ", Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Ablpositive cells," The American Society of Hematology, vol. Blood 96 pp. 3195-3199, 2000.
[8] S. P. Chakrabarty and F. B. Hanson, "Optimal control of drug delivery to brain tumors for a distributed parameters model," presented at Proceedings of the American Control Conference 2005.
[9] K. R. Fister and J. C. Panetta, "Optimal control applied to cell-cycle-specific cancer chemotherapy," SIAM J. Appl.Math, vol. 60, pp. 1059-1072, 2000.
[10] U. Ledzewicz and H. Schattler, "Analysis of a cell cycle specific model for cancer chemotherapy," Biol. Syst, vol. 10, pp. 183, 2002.
[11] Thomas-Schoemann, Audrey, and e. al., "Drug interactions with solid tumour-targeted therapies," Critical Reviews in Oncology/Hematology, vol. 89, pp. 179-196, 2013.
[12] Oliveira, Sabrina, and e. al., "Targeting tumors with nanobodies for cancer imaging and therapy," Journal of Controlled Release, vol. 172, pp. 607-617, 2013.
[13] Yin, Qi, and e. al., "Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor," Advanced drug delivery reviews, vol. 65, pp. 1699-1715, 2013.
[14] K. Takara, et al., "Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy," Journal of Controlled Release, vol. 162, pp. 225-232, 2012.
[15] M. C. Mackey and L. Pujo-Menjouet, "Contribution to the study of periodic chronic myelogenous leukemia," C. R. Biol. 327 vol. 3, pp. 235-244, 2004.
[16] F. Michor and et.al., "Dynamics of chronic myeloid leukemia," Nature vol. 435, pp. 1267-1270, 2005.
[17] S. Nanda, H. Moore, and S. Lenhart, "Optimal control of treatment in a mathematical model of chronic myelogenous Leukemia," Mathematical Biosciences vol. 210, pp. 143-156, 2007.
[18] B. Aïnseba and C. Benosman, "Optimal control for resistance and suboptimal response in CML," Mathematical Biosciences, vol. 227, pp. 81–93, 2010.
[19] R. Borrelli and C. Coleman, Differential Equations: A Modeling Perspective. New York: Wiley, 1998.
[20] J. M. Maciejowski, Multivariable Feedback Design: Addison – Wesley, 1989.
[21] M. Green and D. N. Limebeer, Linear robust control: Prentice – Hall, 1995.
[22] A. Khaki Sedigh, Analysis and Design of Multivariable Control Systems. Tehran: Khajenasir, 2010.
[23] S. Skogestad and I. Postlethwaite, Multivariable Feedback Control Analysis and Design, Second ed: Wiley, 2005.
[24] Q. G. Wang, C. Ye, N. Jaci, and C. C. Hang, "PID Control for Multivariable Processes," LNCIS, Springer Verlag, 2008.
[25] D. H. Owens, "Feedback and Multivariable Systems," IEEE Control engineering series, 1978.
[26] R. V. Patel, Multivariable System Theory and Design: Pergamon press, 1982.
[27] V. V. Kulkarni, M. V. Kothare, and M. G. Safonov, "Decentralized dynamic nonlinear controllers to minimize transmit power in cellular networks, Part I," Systems & Control Letters, 2010.